5 minute read
Sep. 27, 2022

EMA Approval: Lenacapavir (Sunlenca), a First-In-Class HIV Capsid Inhibitor

Drug Hunter Team

In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.

This Premium deep dive into Sunlenca includes:

  • the industry context

  • the clinical data

  • the target rationale

  • the mechanism of action

  • the drug’s origins

Lenacapavir (Sunlenca), chemical structure

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.



Other articles you may be interested in